Nature communications · 2020
Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arnold Matthias, Nho Kwangsik, Kueider-Paisley Alexandra, Massaro Tyler, Huynh Kevin, Brauner Barbara, MahmoudianDehkordi Siamak, Louie Gregory, Moseley M Arthur, Thompson J Will, John-Williams Lisa St, Tenenbaum Jessica D, Blach Colette, Chang Rui, Brinton Roberta D, Baillie Rebecca, Han Xianlin, Trojanowski John Q, Shaw Leslie M, Martins Ralph, Weiner Michael W, Trushina Eugenia, Toledo Jon B, Meikle Peter J, Bennett David A, Krumsiek Jan, Doraiswamy P Murali, Saykin Andrew J, Kaddurah-Daouk Rima, Kastenmüller Gabi
Аннотация
Late-onset Alzheimer's disease (AD) can, in part, be considered a metabolic disease. Besides age, female sex and APOE ε4 genotype represent strong risk factors for AD that also give rise to large metabolic differences. We systematically investigated group-specific metabolic alterations by conducting stratified association analyses of 139 serum metabolites in 1,517 individuals from the AD Neuroimaging Initiative with AD biomarkers. We observed substantial sex differences in effects of 15 metabolites with partially overlapping differences for APOE ε4 status groups. Several group-specific metabolic alterations were not observed in unstratified analyses using sex and APOE ε4 as covariates. Combined stratification revealed further subgroup-specific metabolic effects limited to APOE ε4+ females. The observed metabolic alterations suggest that females experience greater impairment of mitochondrial energy production than males. Dissecting metabolic heterogeneity in AD pathogenesis can therefore enable grading the biomedical relevance for specific pathways within specific subgroups, guiding the way to personalized medicine.